SX-682

N/A

Report date: 2024/01/05 10:45:41
NMEFirst In Class

Base Information

Drug NameSX-682
Drug Alias NameSX-682
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 1 inhibitorsC-X-C motif chemokine receptor 2 inhibitors
TargetsC-X-C motif chemokine receptor 1C-X-C motif chemokine receptor 2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSyntrix Biosystems Inc
China Registration ClassN/A

Develop Information

Active CompaniesSyntrix Biosystems IncRoswell Park Cancer InstituteUniversity Of Rochester +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[17] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A